From Jan 2023, co-chaired the governance committee overseeing the internal preclinical oncology portfolio, including IO, toxin conjugate and radiopharm programs.With heads of chemistry and UK biology, responsible for allocation of resources across the internal and partnered preclinical portfolio to deliver on corporate goals (>100 people and >$50M budget in 2024).

- Built and led the US discovery biology team focused on immuno-oncology (20 scientists).- Guided the UK science team on target selection and prioritization of platform projects.- Supported Bicycle’s discovery collaboration with Genentech.- Supported board and investor interactions, as well as financing and diligence activities.Since joining Bicycle in Jan 2020:- Successfully rebuilt and reoriented the US biology group growing to 20 employees by mid-2022. Established a broad range of functional human immunology and cell biology capabilities to support the Genentech collaboration as well as internal programs. - Delivered successful IND filing for the Nectin-4-targeted CD137 agonist, BT7480. First patient dosed in Nov, 2021 (press release) followed with promising clinical and pharmacodynamic activity in advanced cancer patients (Dec 2023 BCYC R&D day and ESMO 2024 poster). Delivered a related program to IND ready to file in 2023. Delivered in vitro proof-of-concept for a novel NK cell engager program (SITC/AACR posters) and achieved selection of a development candidate.- Supported Genentech collaboration leading to multiple expansions of the partnership and >$23M in new milestone payments (press releases) and contributed to radiopharm deals totaling $95M in upfront payments in 2023 (press releases).- In 2021 and 2022, led nomination and prioritization of targets for prosecution on platform that has since yielded advanced chemical matter for 8 tumor antigens and 4 immune agonist receptors – value creation measured as the upfront payments that Bicycle deals command.

- Guided basic research into tumor heterogeneity and the role of stromal cells in shaping the tumor immune microenvironment: Postdoctoral scientists and external collaborations.- Led teams of scientists focused on target ID, target validation and drug candidate selection in tumor fibrosis and myeloid cell biology (multiple programs in each area). - Drove pipeline strategy and execution as core member of Oncology governance committee.- Co-led clinical development teams for MK-4830, MK-0482 and MK-4621, three first-in-class immuno-oncology drugs.- Business development and licensing in Oncology: Guided initial company interactions and evaluations as well as conducted due diligence assessments and development of deal terms.

Biochemistry and enzymology: Mechanisms of nitric oxide sensing by soluble guanylate cyclase. Supervisor - Michael A. Marletta

Biochemistry and enzymology: Mechanism of action of inhibitors of bacterial cell wall biosynthesis. Supervisor - Timothy D. H. Bugg